Patents by Inventor Pascale Fouqueray

Pascale Fouqueray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating subjects having diabetes with chronic kidney disease
    Patent number: 12036226
    Abstract: The present disclosure is directed to a method of treating prediabetes or type 1 or type 2 diabetes mellitus comprising administering to a subject in need thereof an effective amount of imeglimin, wherein the subject has chronic kidney disease.
    Type: Grant
    Filed: January 26, 2022
    Date of Patent: July 16, 2024
    Assignee: Poxel SA
    Inventors: Bill Symonds, Steve Piscitelli, Karen Segal, Ruby Holder, Sophie Bozec, Sébastien Bolze, Pascale Fouqueray, Christophe Arbet-Engels, Julie Dubourg, Paul Strumph, Brandon Dale Swift, Margaret Smith Fletcher
  • Use of a thienopyridone derivative in the treatment of adrenoleukodystrophy or adrenomyeloneuropathy
    Patent number: 11850238
    Abstract: The invention relates to the use of a thienopyridone derivative, or a pharmaceutical composition comprising the same, in the treatment of genetic neurodegenerative diseases selected from adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN).
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: December 26, 2023
    Assignee: POXEL
    Inventors: Sébastien Bolze, Pascale Fouqueray, Sophie Hallakou-Bozec
  • USE OF A THIENOPYRIDONE DERIVATIVE IN THE TREATMENT OF DIABETIC NEPHROPATHY
    Publication number: 20230149370
    Abstract: The invention relates to the use of a thienopyridone derivative of Formula (I), or its pharmaceutically acceptable salts and/or solvates, or a pharmaceutical composition comprising the same, in the treatment of diabetic nephropathy.
    Type: Application
    Filed: March 26, 2021
    Publication date: May 18, 2023
    Inventors: SÉBASTIEN BOLZE, PASCALE FOUQUERAY, SOPHIE HALLAKOU-BOZEC
  • USE OF A THIENOPYRIDONE DERIVATIVE IN THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
    Publication number: 20230120204
    Abstract: The invention relates to the use of a thienopyridone derivative, or a pharmaceutical composition comprising the same, in the treatment of autosomal dominant polycystic kidney disease (ADPKD).
    Type: Application
    Filed: April 2, 2021
    Publication date: April 20, 2023
    Inventors: SÉBASTIEN BOLZE, PASCALE FOUQUERAY, SOPHIE HALLAKOU-BOZEC
  • USE OF A THIENOPYRIDONE DERIVATIVE IN THE TREATMENT OF ADRENOLEUKODYSTROPHY OR ADRENOMYELONEUROPATHY
    Publication number: 20230112080
    Abstract: The invention relates to the use of a thienopyridone derivative, or a pharmaceutical composition comprising the same, in the treatment of genetic neurodegenerative diseases selected from adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN).
    Type: Application
    Filed: March 26, 2021
    Publication date: April 13, 2023
    Inventors: SÉBASTIEN BOLZE, PASCALE FOUQUERAY, SOPHIE HALLAKOU-BOZEC
  • METHODS OF TREATING SUBJECTS HAVING DIABETES WITH CHRONIC KIDNEY DISEASE
    Publication number: 20220387437
    Abstract: The present disclosure is directed to a method of treating prediabetes or type 1 or type 2 diabetes mellitus comprising administering to a subject in need thereof an effective amount of imeglimin, wherein the subject has chronic kidney disease.
    Type: Application
    Filed: January 26, 2022
    Publication date: December 8, 2022
    Inventors: Bill Symonds, Steve Piscitelli, Karen Segal, Ruby Holder, Sophie Bozec, Sébastien Bolze, Pascale Fouqueray, Christophe Arbet-Engels, Julie Dubourg, Paul Strumph, Brandon Dale Swift, Margaret Smith Fletcher
  • Methods of treating subjects having diabetes with chronic kidney disease
    Patent number: 11266652
    Abstract: The present disclosure is directed to a method of treating prediabetes or type 1 or type 2 diabetes mellitus comprising administering to a subject in need thereof an effective amount of imeglimin, wherein the subject has chronic kidney disease.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: March 8, 2022
    Assignee: POXEL SA
    Inventors: Bill Symonds, Steve Piscitelli, Karen Segal, Ruby Holder, Sophie Bozec, Sebastien Bolze, Pascale Fouqueray, Christophe Arbet-Engels, Julie Dubourg, Paul Strumph, Brandon Dale Swift, Margaret Smith Fletcher
  • METHODS OF TREATING SUBJECTS HAVING DIABETES WITH CHRONIC KIDNEY DISEASE
    Publication number: 20200215072
    Abstract: The present disclosure is directed to a method of treating prediabetes or type 1 or type 2 diabetes mellitus comprising administering to a subject in need thereof an effective amount of imeglimin, wherein the subject has chronic kidney disease.
    Type: Application
    Filed: March 9, 2020
    Publication date: July 9, 2020
    Inventors: Bill SYMONDS, Steve PISCITELLI, Karen SEGAL, Ruby HOLDER, Sophie BOZEC, Sebastien BOLZE, Pascale FOUQUERAY, Christophe ARBET-ENGELS, Julie DUBOURG, Paul STRUMPH, Brandon Dale SWIFT, Margaret Smith FLETCHER
  • Treatment of type 1 diabetes
    Patent number: 9271984
    Abstract: The present invention relates to triazine derivatives of formula (I) for their use in the treatment of type 1 diabetes mellitus, and to compositions comprising said triazine derivatives.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: March 1, 2016
    Assignee: POXEL
    Inventors: Pascale Fouqueray, Daniel Cravo, Sophie Hallakou-Bozec, Sébastien Bolze
  • TREATMENT OF TYPE 2 DIABETES
    Publication number: 20130131065
    Abstract: The present invention relates to triazine derivatives of Formula I for their use in the treatment of Type 2 diabetes, and to compositions comprising said triazine derivatives.
    Type: Application
    Filed: June 9, 2011
    Publication date: May 23, 2013
    Inventors: Pascale Fouqueray, Daniel Cravo, Sophie Hallakou-Bozec, Sébastien Bolze
  • TREATMENT OF TYPE 1 DIABETES
    Publication number: 20130131066
    Abstract: The present invention relates to triazine derivatives of formula (I) for their use in the treatment of type 1 diabetes mellitus, and to compositions comprising said triazine derivatives.
    Type: Application
    Filed: June 9, 2011
    Publication date: May 23, 2013
    Applicant: POXEL
    Inventors: Pascale Fouqueray, Daniel Cravo, Sophie Hallakou-Bozec, Sébastien Bolze
  • USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA
    Publication number: 20100160410
    Abstract: The use of a pentadienoic acid derivative of formula (I) for the preparation of a medicament for the prevention or treatment of hyperuricemia and/or one or several associated disorders or diseases, and/or for reducing the serum uric acid level of a subject. Medical compositions for these prevention and/or treatment, comprising such a pentadienoic acid derivative.
    Type: Application
    Filed: January 13, 2010
    Publication date: June 24, 2010
    Inventors: Robert Boizel, Pascale Fouqueray, Daniel Guerrier, Jean-Jacques Zeiller, Bertrand Brutzkus
  • Use of pentadienoic acid derivatives for the treatment of hyperuricemia
    Publication number: 20070099854
    Abstract: The use of a pentadienoic acid derivative of formula (I) for the preparation of a medicament for the prevention or treatment of hyperuricemia and/or one or several associated disorders or diseases, and/or for reducing the serum uric acid level of a subject. Medical compositions for these prevention and/or treatment, comprising such a pentadienoic acid derivative.
    Type: Application
    Filed: November 2, 2004
    Publication date: May 3, 2007
    Inventors: Robert Boizel, Pascale Fouqueray, Daniel Guerrier, Jean-Jacques Zeiller, Bertrand Brutzkus